Method for making a homogenous vaccine composition comprising a conjugate of EGF and 64K for the treatment of tumors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 23, 2014
Grant Date -
Feb 14, 2013
app pub date -
Jan 10, 2012
filing date -
Jun 29, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully